The Goal of Prognostic Testing is to Predict Patient Outcomes

Myriad’s prognostic tests are designed to provide you and your patients with information about the aggressiveness of their cancer, allowing you to make better and more informed treatment decisions. Prognostic testing enables you to more effectively define a personalized treatment or monitoring strategy for each patient’s cancer.

Predicting Tumor Aggressiveness

No two cancers are the same, and it can be difficult to predict which tumors are slow-growing and which are likely to progress or metastasize. Prognostic tests that measure the expression of genes involved in cell cycle progression provide information that, when used in conjunction with other clinical features, can help predict disease outcome and guide treatment.

In Prostate Cancer

Managing localized prostate cancer presents a unique challenge because prostate cancer is highly variable and some tumors are slow-growing or nonaggressive. Monitoring tests such as prostate-specific antigen (PSA) level and Gleason score provide information on disease progression, but do not measure tumor aggressiveness. Understanding the aggressiveness of each patient’s specific prostate cancer can help you and your patient feel more confident about choosing the most appropriate treatment plan.*1,2 Prolaris® has been shown to effectively provide this information.

Learn More About Prolaris

 

In Early-Stage Lung Cancer

Stage in non-small cell lung adenocarcinoma provides an indicator of lung cancer progression. However, cancer stage alone does not reveal the aggressiveness of the disease. Having accurate information about the aggressiveness of a particular patient’s lung cancer provides more insight into their five-year survival potential and the best approach to treatment.* Myriad myPlan® Lung Cancer can help provide this information.

Learn more about Myriad myPlan Lung Cancer

Myriad Prolaris and myPlan Lung Cancer

Prognostic tests such as Myriad’s Prolaris for prostate cancer and Myriad myPlan Lung Cancer can provide accurate information about the aggressiveness of individual cancers.1,3,4,5,6 These tests analyze the expression of cell proliferation genes in the tumor to measure how fast the tumor cells are dividing. This information can be used along with other traditional clinical features of cancer progression to determine the risks associated with the patient’s disease, as well as personalize treatment decisions.*

In addition to Prolaris and Myriad myPlan Lung Cancer, Myriad is currently investigating prognostic tests for predicting the aggressiveness of other types of cancer.

*Any discussion of medical management options is for general informational purposes only and does not constitute a recommendation.  While genetic testing and medical society guidelines provide important and useful information, all medical management decisions should be made based on consultation between each patient and his or her healthcare professional.

References

1. Cooperberg MR, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clinical Oncol 2013:31(11):1428-34.

2. Crawford ED, et al. Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry. Curr Med Res Opin 2014 Mar 13 [Epub ahead of print]

3. Freedland SJ, et al. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int J Radiat Oncol, Biol, Phys 2013:86(5):848-853.

4. Wistuba II, Behrens C, Lombardi F, et al. Prognostic Marker in Early Stage Lung Adenocarcinoma. Clinical Cancer Research. November 15, 2013 19:6261-6271

5. Bueno R, et al. Validation of a molecular and pathological model for fiver-year mortality risk in patients with early stage lung adenocarcinoma. J Thorac Oncol 2015; 10:67-73.

6. Rakha E, et al. Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators. Eur J Cancer 2015; 51:1897-1903